Ceftobiprole medocaril

Trade Name:

Zeftera

Manufacturer/Distributor:

Janssen-Ortho

Classification:

Cephalosporin antibiotic

ATC Class:

J01DI01 Ceftobiprole medocaril

Status:

discontinued

Date Marketed in Canada (yyyy/mm/dd):

2010/04/16

Presentation:

Vial for injection: 500 mg; DIN: 02313103

Comments:

Discontinued in Canada following regulatory recommendations in the United States and the European Union to not approve Zeftera ( due to concerns regarding the conduct of clinical trials). Further information can be obtained from the Health Canada Advisories, Warning and Recalls website (http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/index-eng.php).

Keywords:

ceftobiprole

Keywords:

drug discontinuation

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Polyethylene glycol 3350	Pegalax	Laxative
Pomalidomide	Pomalyst	Antineoplastic agent; immunmodulator	2014/02/24
Ponesimod	Ponvory	Sphingosine 1-phosphate receptor modulator	2021/04/28
Prasugrel	Effient	Platelet aggregation inhibitor	2010/05/17
Prasugrel	Effient	Antiplatelet agent	2020/01/31
Pregabalin	Lyrica	Analgesic
Probenecid	Benuryl	Uricosuric agent
Progesterone	Endometrin	Progestin	2010/02/21
Propiverine	Mictoryl; Mictoryl Pediatric	Anticholinergic and antispasmodic agent	2017/04/13
Propofol	Propofol Injection	Anesthetic, sedative	2010/06/01
Propoxyphene	Darvon-N; 642	Narcotic
Prucalopride	Resotran	Enterokinetic agent	2012/01/13
Regorafenib	Stivarga	Antineoplastic agent	2013/03/11
Ribociclib	Kisqali	Antineoplastic agent	2018/11/26
Rilpivirine	Edurant	Antiviral agent	2011/08/08
Risankizumab	Skyrizi	Interleukin-23 inihbitor	2019/05/13
Risedronate	Actonel DR	Bone metabolism regulator	2011/09/28
Risedronate + Calcium carbonate	Actonel APC
Risedronate sodium	Actonel	Bisphosphonate
Roflumilast	Daxas	Phosphodiesterase 4 (PDE4) Inhibitor	2010/11/25
Romosozumab	Evenity	Bone formation agent	2019/08/12
Rosiglitazone + glimepiride	Avandaryl		2011/03/31
Rotigotine	Neupro	Antiparkinsonian agent / Dopamine agonist	2013/09/12
Rufinamide	Banzel	Antiepileptic	2011/09
Rupatadine	Rupall	Antihistamine, second generation	2017/01/25
Ruxolitinib	Jakavi	Antineoplastic agent	2012/07/18
Sacubitril + valsartan	Entresto	Endopeptidase inhibitor, angiotension II receptor antagonist	2015/11/13
Safinamide	Onstryv	Monoamine oxidase B inhibitor	2019/07/10
Salicylic acid + Triclosan	Panoxyl Clear Acne Cleansing Gel
Sapropterin hydrochloride	Kuvan	Used in phenylketonuria	2010/07/05
Sarilumab	Kevzara	Disease modifying anti-rheumatic drug	2017/08/16
Satralizumab	Enspryng	Immunosuppresant	2020/08/26
Saxagliptin	Onglyza	Dipeptidyl peptidase-4 inhibitor; Incretin enhancer	2009/09/14
Saxagliptin + dapagliflozin	Qtern	Oral antihyperglycemic agent	2018/03/20
Saxagliptin + metformin	Komboglyze	Oral antihyperglycemic agent	2013/04/25
Selexipag	Uptravi	Prostacyclin receptor antagonist	2016/04/21